PedAM
Pediatric Disease Annotations & Medicines
| Disease | hyperglycemia |
| Phenotype | |type 2 diabetes |
| Sentences | 186 |
| PubMedID- 25349949 | Conclusion: depression in type 2 diabetes was closely associated with hyperglycemia and hypoglycemia, which might be partly mediated through poor treatment adherence. |
| PubMedID- 23295502 | Clinical trial results have shown further that two glp-1 receptor agonists (glp-1 ras), exenatide and liraglutide, which are approved for the treatment of hyperglycemia in patients with type 2 diabetes, also produce weight loss in overweight subjects without diabetes. |
| PubMedID- 24516103 | Dipeptidyl peptidase-4 inhibitors prevent the degradation of incretin hormones and reduce postprandial hyperglycemia in patients with type 2 diabetes mellitus. |
| PubMedID- 20150286 | Despite their hyperglycemia, patients with type 2 diabetes tend to have elevated fasting glucagon levels and exaggerated glucagon responses to meal ingestion (5). |
| PubMedID- 24465132 | When contraindications to its use exist or patients cannot tolerate it due to adverse effects, clinicians have a variety of other classes of agents to treat hyperglycemia associated with type 2 diabetes mellitus. |
| PubMedID- 21354873 | [recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes. |
| PubMedID- 21437094 | The glp-1 receptor belongs to the g-protein coupled family of receptors, and it is known to be present in the pancreas, gastrointestinal tract, brain, and other tissues, including the heart.16 glp-1 receptors have also been identified in vagal afferent neurons in the rat nodose ganglion, and studies suggest that glp-1 may act on target organs not only through classic hormonal mechanisms but also through neural pathways.17,18 in the pancreas, important actions of glp-1 include the enhancement of glucose-dependent insulin synthesis and secretion, and stimulation of beta-cell proliferation.19 glp-1 also inhibits inappropriate alpha-cell glucagon secretion, which occurs despite hyperglycemia in patients with type 2 diabetes.20 this reduction of glucagon secretion lessens hepatic glucose output and contributes to the antidiabetic effects of glp-1. |
| PubMedID- 23617251 | Aims: it is necessary to evaluate glucose variability and postprandial hyperglycemia in patients with well-controlled type 2 diabetes mellitus because of the limitations associated with hemoglobin a1c (hba1c) measurements. |
| PubMedID- 20107105 | hyperglycemia in type 2 diabetes is caused by decreased insulin secretion due to progressive β-cell dysfunction, insulin resistance in peripheral tissues, and increased hepatic glucose output (1,2). |
| PubMedID- 26213526 | It has been stated that in diabetes activity of gt is increased, therefore inhibitors of glycogen phosphorylase have been studied as potential therapy for attenuating hyperglycemia associated with type 2 diabetes (baker et al. |
| PubMedID- 24612502 | The maximum effective dose of metformin to treat hyperglycemia in patients with type 2 diabetes is 1000 mg twice daily. |
| PubMedID- 21410975 | The objective of this analysis was to examine retrospectively the cv safety of exenatide bid, a glp-1 receptor agonist approved for treating hyperglycemia in patients with type 2 diabetes not adequately controlled with diet and exercise. |
| PubMedID- 21397778 | Objective: to assess how medication adherence affects treatment modifications for hypertension and hyperglycemia in patients with type 2 diabetes. |
| PubMedID- 21838680 | The increased oxidative stress in subjects with type 2 diabetes is a consequence of several abnormalities, including hyperglycemia, insulin resistance, hyperinsulinemia, and dyslipidemia, each of which contributes to mitochondrial superoxide overproduction in endothelial cells of large and small vessels as well as the myocardium. |
| PubMedID- 21193625 | The ada and the easd published an expert consensus statement on the approach to management of hyperglycemia in individuals with type 2 diabetes (82). |
| PubMedID- 20876838 | Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugs. |
| PubMedID- 24488695 | Mitiglinide is a rapid- and short-acting insulinotropic sulfonylurea receptor ligand that is known to improve postprandial hyperglycemia in patients with type 2 diabetes. |
| PubMedID- 22111038 | It is well established that chronic hyperglycemia in patients with type 2 diabetes mellitus causes progressive deterioration of β-cell function. |
| PubMedID- 21357363 | Since 1995 there have been multiple new drugs approved by the food and drug administration for the treatment of hyperglycemia in patients with type 2 diabetes, including the biguanide metformin, α-glucosidase inhibitors, thiazolidinediones, glinides, glp-1 analogs, amylin analogs, dipeptidyl peptidase-iv inhibitors (31), a bile acid sequestrant (32), and most recently a dopamine receptor agonist (33). |
| PubMedID- 23788837 | The cause of hyperglycemia in type 2 diabetes is usually a combination of insulin resistance and increased hepatic glucose production. |
| PubMedID- 23231438 | In clinical trials, both exenatide formulations reduced hyperglycemia in patients with type 2 diabetes mellitus (t2dm) and were associated with weight loss. |
| PubMedID- 23565389 | Despite an increasing number of therapeutic options, optimal management of hyperglycemia in patients with type 2 diabetes (t2d) remains an elusive goal for a majority of patients. |
| PubMedID- PMC3447838 | Management of hyperglycemia in type 2 diabetes: a patient-centered approach. |
| PubMedID- 21775756 | However, the failure to completely normalize fasting hyperglycemia in patients with type 2 diabetes appears to be consistent with both clinical practice and previous clinical studies (14) and provides a rationale for adding complimentary treatment options, such as short-acting insulin (24) or incretin-based therapies (25), if normoglycemia cannot be achieved with basal insulin alone. |
| PubMedID- 25538310 | Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the american diabetes association and the european association for the study of diabetes. |
| PubMedID- 21172030 | Agents that modulate bile acids may potentially affect both cholesterol and glucose metabolism, and hence dyslipidemia and hyperglycemia, in patients with type 2 diabetes [69,71,72]. |
| PubMedID- 21886908 | type 2 diabetes mellitus-induced hyperglycemia in patients with nafld and normal lfts: relationship to lipid profile, oxidative stress and pro-inflammatory cytokines. |
| PubMedID- 21115766 | The second-meal effect can be applied simply and practically to improve postbreakfast hyperglycemia in people with type 2 diabetes. |
| PubMedID- 26587047 | Nevertheless, in a randomized, blinded, crossover study, a single oral dose of quercetin (400 mg) effectively suppressed postprandial hyperglycemia in patients with type 2 diabetes [105]. |
| PubMedID- 20028938 | During intralipid infusion, the auc for glucose levels (assuming linear interpolation) were 5,204 ± 1,222 in kpdm, 6,420 ± 1,332 in type 2 diabetes with hyperglycemia, and 5,230 ± 436 in nondiabetic control group. |
| PubMedID- 24444522 | The therapeutic armamentarium for the treatment of hyperglycemia in type 2 diabetes mellitus is still inadequate. |
| PubMedID- 24332968 | Beta cell failure in type 2 diabetes (t2d) is associated with hyperglycemia, but the mechanisms are not fully understood. |
| PubMedID- 26220945 | Objective: skipping breakfast has been consistently associated with high hba1c and postprandial hyperglycemia (pphg) in patients with type 2 diabetes. |
| PubMedID- 23099862 | Furthermore, experimental suppression of hyperglucagonemia corrects postprandial hyperglycemia in individuals with type 2 diabetes (7). |
| PubMedID- 23704680 | Personalized management of hyperglycemia in type 2 diabetes: reflections from a diabetes care editors' expert forum. |
| PubMedID- 22068600 | Our results suggest that pamp is a potential upstream regulator of hyperglycemia in type 2 diabetes. |
| PubMedID- 20427697 | Nevertheless, the studies by madsbad and højberg clearly demonstrate that reducing the hyperglycemia in patients with type 2 diabetes can also elicit significant improvements in the incretin effect. |
| PubMedID- 24159187 | Personalized management of hyperglycemia in type 2 diabetes: reflections from a diabetes care editors’ expert forum. |
| PubMedID- 23715754 | hyperglycemia in type 2 diabetes results from a combination of insulin resistance in several insulin target tissues (including liver, skeletal muscle, and adipose tissue) and β-cell dysfunction (1,2). |
| PubMedID- 24223860 | The management of hyperglycemia in type 2 diabetes can be complex for people with diabetes and health care providers alike, as the benefits of optimizing glycemic control through treatment intensification need to be balanced with the needs, preferences and drug tolerances of each individual person [3], [4], [5]. |
| PubMedID- 22996184 | Management of hyperglycemia in type 2 diabetes: a patient-centered approach. |
| PubMedID- 24843506 | Association between coefficients of variation of the r-r intervals on electrocardiograms and post-challenge hyperglycemia in patients with newly diagnosed type 2 diabetes. |
| PubMedID- 25452853 | Glycated albumin, fructosamine, and 1,5-anhydroglucitol (1,5-ag) are of growing interest as alternative markers of hyperglycemia in persons with type 2 diabetes. |
| PubMedID- 23721170 | Management of hyperglycemia in type 2 diabetes: evidence and uncertainty. |
| PubMedID- 20705776 | The objective of this research is to gain a greater understanding of the cause of fasting and postprandial hyperglycemia in people with type 2 diabetes. |
| PubMedID- 22590838 | Perioperative hyperglycemia is common in patients with type 2 diabetes undergoing coronary artery bypass graft (cabg) surgery and there is a direct relation between postoperative hyperglycemia and mortality rate in these patients. |
| PubMedID- 20334663 | Potential agents to target postprandial hyperglycemia in patients with type 2 diabetes include α-glucosidase inhibitors and glinide drugs. |
| PubMedID- 24444521 | Several experimental and clinical studies suggest that pharmacological blockade of this transporter might be beneficial in the management of hyperglycemia in patients with type 2 diabetes. |
| PubMedID- 25664181 | This may be related to the american diabetes association and the european association for the study of diabetes; the recommended approach to management of hyperglycemia in patients with type 2 diabetes begins with lifestyle modification and low-dose metformin.3536 from there, clinicians are encouraged to check blood glucose and hba1c levels and titrate the metformin dosing, so as to minimize gastrointestinal side effects from the medication. |
| PubMedID- 25595348 | Thus, a consensus statement from the american diabetes association and the european association for the study of diabetes on the management of hyperglycemia in type 2 diabetes was published in april 2012. |